LYMPHOID TUMORS

• The Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination as Induction Therapy in Patients with Multiple Myeloma Complicated by the End-Stage Renal Disease

  Sergei Vyacheslavovich Semochkin, E.I. Zhelnova, V.I. Kazey, A.V. Cherkasova, A.G. Nikiforova, N.F. Frolova, E.A. Baryakh, K.V. Yatskov, E.A. Karimova, O.N. Kotenko, E.N. Misyurina

  360-369

  01.10.2024

• Sarcoid-like Pulmonary Lesion in a Female Patient with Multiple Myeloma and Systemic AL Amyloidosis Treated with Daratumumab: A Case of Spontaneous Regression of Lung Tissue Changes upon Drug Withdrawal

  Irina Germanovna Rekhtina, V.A. Khyshova, A.M. Kovrigina, M.A. Silaev, L.P. Mendeleeva

  370-375

  01.10.2024

• Bone Marrow Lymphocyte Subpopulation in Chronic Lymphocytic Leukemia Patients with Different Responses to Chemotherapy

  Olesya Nikolaevna Selyutina, E.Yu. Zlatnik, N.K. Guskova, I.A. Novikova, I.B. Lysenko, A.B. Sagakyants, T.F. Pushkareva, L.Yu. Vladimirova

  376-383

  01.10.2024

• The Impact of Routing on a Speedy Diagnosis of Acute Leukemia in Children: Results of a Regional Study

  I.S. Dolgopolov, Maksim Yurevich Rykov

  384-389

  01.10.2024

• Multiple Myeloma: Simulation of Therapy Scenarios Using the Monte Carlo Method

  Aleksander Sergeevich Luchinin, A.A. Semenova, S.V. Semochkin

  246-255

  01.07.2024

• Treatment Outcomes in Primary Mediastinal Large B-Cell Lymphoma. Experience of the AF Tsyb Medical Radiological Research Center (Obninsk)

  Alena Yurevna Terekhova, N.A. Falaleeva, A.B. Galitsyna, A.M. Chelmakov, A.A. Vovchenko, N.A. Riabikina, A.A. Danilenko, T. I. Bogatyreva

  225-236

  01.07.2024

• Impact of Cardiac Disease on Prognosis in Patients with Systemic AL Amyloidosis

  Olga Vladislavovna Pirogova, O.V. Kudyasheva, M.V. Chernous, M.A. Gorodnova, D.K. Lamden, K.A. Novitskaya, A.G. Smirnova, A.V. Yakovleva, V.A. Ionin, A.M. Ananin, I.S. Moiseev, A.D. Kulagin

  237-245

  01.07.2024

• KRAS/NRAS Gene Mutations and the Efficacy of Bortezomib-Based Triplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma

  Anna Mikhailovna Sergeeva, V.L. Surin, Yu.A. Chabaeva, A.A. Kraizman, M.V. Solovev, S.M. Kulikov, L.P. Mendeleeva

  256-265

  01.07.2024

• The Prognostic Value of Cytotoxic CD8-Positive Т-Lymphocytes of the Reactive Tumor Microenvironment in Diffuse Large B-Cell Lymphoma

  Elena Viktorovna Vaneeva, V.A. Rosin, D.A. Dyakonov, N.V. Glubokovskikh

  266-272

  01.07.2024

• Ibrutinib in Chronic Lymphocytic Leukemia Therapy for High- and Very-High-Risk Patients over 60 Years of Age

  Nadezhda Viktorovna Kurkina, E.A. Repina, E.I. Gorshenina, V.O. Kurkina, P.V. Volkova, A.A. Repin

  37-42

  17.05.2024

• Treatment of Patients with Local Stages of Newly Diagnosed Classical Hodgkin Lymphoma: A Literature Review, Current Approaches, and Our Own Experience

  Evgeniya Viktorovna Paramonova, Yu.I. Klyuchagina, M.Yu. Kichigina, D.N. Tupitsyna, V.O. Shpirko, A.V. Arakelyan, A.A. Semenova, E.A. Demina, O.P. Trofimova, A.S. Subbotin, M.A. Senchenko, G.S. Tumyan

  27-36

  17.05.2024

• Therapy Optimization in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Efficacy and Safety of the R-SD-EPOCH ± HDMTX Program Under Single-Center Non-Randomized Prospective Clinical Trial (Preliminary Results)

  Marat Albertovich Mingalimov

  173-179

  01.04.2024

• CD20-Positive B-Lymphocytes in the Reactive Tumor Microenvironment as an Independent Immunohistochemical Prognostic Factor in Nodular Sclerosis Classical Hodgkin Lymphoma

  Maksim Sergeevich Minaev

  166-172

  01.04.2024

• Diagnostic Potential of Regulatory Non-Coding Protein RNAs in Chronic Lymphocytic Leukemia

  Igor Alekseevich Olkhovskii

  154-165

  01.04.2024

• The Role of Polymorphic Variants of Р450 Cytochrome Genes as well as Genes GSTP1 and MDR1 in Toxic Complications of Program Drug Chemotherapy for Classical Hodgkin Lymphoma

  Yana Yurevna Shebunyaeva

  141-153

  01.04.2024

• Primary Prevention of Neutropenia by Empegfilgrastim in Patients with Advanced Stages of Classical Hodgkin Lymphoma Treated with Intensive First-Line Chemotherapy with a Modified 6-Cycle Program EACODD-14 Under the Protocol “LKh-Rossiya-1”

  Anna Anatolevna Spornik, N.S. Vasilev, A.A. Samoilova, A.A. Mamedova, V.S. Bogatyrev, E.G. Smirnova, A.A. Bannikova, A.A. Rukavitsyn, N.S. Shorokhov, N.E. Mochkin, V.O. Sarzhevskii, E.A. Demina, V.Ya. Melnichenko

  370-379

  28.09.2023

• Follicular Lymphoma of Grades 1–3А With and Without t(14;18)(q32;q21): A Prognosis, Choice of Chemotherapy and Its Outcomes

  Ekaterina Sergeevna Nesterova, E.E. Zvonkov, A.M. Kovrigina, T.N. Obukhova, B.V. Biderman, A.B. Sudarikov, Ya.K. Mangasarova, A.U. Magomedova, A.K. Smolyaninova, S.M. Kulikov, E.N. Parovichnikova

  361-369

  28.09.2023

• Endoscopic Semiotics of the Gastritis-Like Form of Primary Gastric Non-Hodgkin Lymphomas

  Valeriya Vitalevna Lozovaya, O.A. Malikhova, A.O. Tumanyan

  380-386

  28.09.2023

• Expression of the WNT Family Genes in Multiple Myeloma Patients with Different Chemotherapy Response

  Natella Iosifovna Enukashvili, L.A. Belik, I.I. Kostroma, N.Yu. Semenova, V.A. Balashova, D.V. Baram, S.V. Gritsaev, S.S. Bessmeltsev, S.V. Sidorkevich, I.S. Martynkevich

  294-302

  09.06.2023

• Multiple Myeloma Complicated by Bone Plasmacytomas: Pathogenesis, Clinical Features, Treatment Approaches (A Literature Review)

  Elizaveta Andreevna Mamaeva, M.V. Solov’eva, L.P. Mendeleeva

  303-310

  09.06.2023